Sanofi Pasteur MSD To Commercialise New 6-in-1 Paediatric Vaccine in European Markets
Vaccine submitted to European Medicines Agency for licence review
Lyon: 18th October 2012 – Sanofi Pasteur MSD plans to licence and commercialise an innovative 6-in-1 paediatric vaccine in its European territories. The new hexavalent vaccine, developed by Sanofi Pasteur, is the only fully liquid, ready to use 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b. "This is a landmark for our company as we hope to provide physicians in Europe with a readyto- use hexavalent vaccine that will raise the standard of care in vaccination for millions of infants," said Jean-Paul Kress, MD, President of Sanofi Pasteur MSD. "This clearly reflects our commitment to bring innovative new vaccines to the European market and it shows the benefits of being able to draw upon the collective expertise of our joint venture. With this new 6-in-1 vaccine, Sanofi Pasteur MSD now has a broad paediatric vaccine portfolio that allows us to provide a wide range of vaccine solutions for our customers."
Sanofi Pasteur MSD is a joint venture in Europe between Sanofi Pasteur, the vaccines division of Sanofi, and Merck, known as MSD outside the United States and Canada. The vaccine has been submitted by Sanofi Pasteur MSD to the European Medicines Agency (EMA) for licence within the European Union and upon approval the company will commercialise it in its European territories under its own brand name.
About Sanofi Pasteur MSD
Sanofi Pasteur MSD is a joint venture between Sanofi Pasteur, the vaccine division of Sanofi, and Merck, known as MSD outside the USA and Canada. Combining innovation and expertise, Sanofi Pasteur MSD is the only company in Europe dedicated exclusively to vaccines. Sanofi Pasteur MSD is able to draw on the research expertise of Sanofi Pasteur and Merck to focus on the development of new vaccines for Europe to improve the acceptability, efficacy and tolerability of vaccination.
For further information contact:
Senior Director External Communications Europe
Sanofi Pasteur MSD
Tel : +33 4 37 28 4040
Mob :+33 6 33 46 1365